Search alternatives:
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
mediate decrease » mediated defense (Expand Search)
cause decreased » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
mean decrease » a decrease (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
mediate decrease » mediated defense (Expand Search)
cause decreased » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
mean decrease » a decrease (Expand Search)
-
1
-
2
-
3
-
4
-
5
Regenerating axons are increased by ATRA and decreased by clodronate.
Published 2021“…Compared to PBS-treated, the number of regenerating axons is doubled by ATRA treatment, decreased by 30% by clodronate, and, in the case of ATRA combined with clodronate, is not significantly different.…”
-
6
-
7
-
8
-
9
Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.
Published 2021“…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …”
-
10
Capsaicin, pyridoxine, vincristine sulfate and ionomycin significantly decreased axon length ratio but only pyridoxine had no impact on neurotoxicity.
Published 2024“…(<b>C</b>) Pyr at 500 μM significantly decreased axon length ratio over time and was significantly lower than PBS control by day 3. …”
-
11
-
12
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 305 units from 5 recording sessions, n<sub>APP/PS1</sub> = 180 units from 4 recording sessions). …”
-
13
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
14
-
15
Depletion of TbSWR1 caused a decrease of reporter luciferase activity within a PTU.
Published 2022Subjects: -
16
-
17
-
18
-
19
-
20